MAP2K2 Antibody

Code CSB-PA013411GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
Cardiofaciocutaneous syndrome antibody; CFC syndrome antibody; CFC4 antibody; Dual specificity mitogen activated protein kinase kinase 2 antibody; Dual specificity mitogen-activated protein kinase kinase 2 antibody; ERK activator kinase 2 antibody; FLJ26075 antibody; MAP kinase kinase 2 antibody; map2k2 antibody; MAPK / ERK kinase 2 antibody; MAPK/ERK kinase 2 antibody; MAPKK 2 antibody; MAPKK2 antibody; MEK 2 antibody; MEK2 antibody; Microtubule associated protein kinase kinase 2 antibody; Mitogen activated protein kinase kinase 2 antibody; Mitogen activated protein kinase kinase 2 p45 antibody; MKK 2 antibody; MKK2 antibody; MP2K2_HUMAN antibody; OTTHUMP00000165826 antibody; OTTHUMP00000165827 antibody; PRKMK 2 antibody; PRKMK2 antibody
Raised in
Species Reactivity
Human MAP2K2
Immunogen Species
Homo sapiens (Human)
Purification Method
Antigen Affinity Purified
It differs from different batches. Please contact us to confirm it.
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation.
Gene References into Functions
  1. Data show that SAM and SH3 domain containing 1 protein (SASH1) binds with mitogen-activated protein kinase kinase 2 (MAP2K2), and SASH1 mutations promote binding between SASH1 and MAP2K2. PMID: 28382689
  2. findings demonstrate the interaction of tRNA with MEK2 in pancreatic cancer cells and suggest that tRNA may impact MEK2 activity in cancer cells PMID: 27301426
  3. MEK2 was essential for the phosphorylation of MKK3/MKK6 and p38 MAPK that directly impacted on cyclin D1 expression. PMID: 27181679
  4. High MEK2 expression is associated with inflammation. PMID: 28178421
  5. there were significant decreases in intercellular adhesion molecules 1 (ICAM1), ezrin (EZR), mitogen-activated protein kinase kinase 2 (MAP2K2), and nitric oxide synthase 3 (NOS3) gene expressions in metabolic syndrome patients. PMID: 26956845
  6. The patient showed a paternally inherited 16p13.11 microduplication and a de novo 19p13.3 microdeletion involving the mitogen-activated protein kinase kinase 2 gene (MAP2K2), in which mutations cause the cardio-facio-cutaneous (CFC) syndrome PMID: 27751966
  7. We report on a fourth familial case with transmission of CFC syndrome from father to son due to a novel heterozygous sequence change c.376A>G (p.N126D) in exon 3 of MEK2 gene. PMID: 25487361
  8. MK2 attenuates dendritic cell-mediated Th1 differentiation and autoimmune encephalomyelitis. PMID: 26078274
  9. Our cohort of seven individuals with MEK2 deletions has overlapping features associated with RASopathies. PMID: 23379592
  10. Both ACE inhibition and MEK1/2 inhibition have beneficial effects on left ventricular function in Lmna(H222P/H222P) mice and both drugs together have a synergistic benefit when initiated after the onset of left ventricular dysfunction. PMID: 25218145
  11. we report familial patients with multiple cafe au lait spots and Noonan syndrome-like facial features who carried mutations in MAP2K2. PMID: 24311457
  12. osteosarcoma patients whose tumors expressed pMEK2 had a poorer clinical outcome than those whose tumors did not. PMID: 22935974
  13. MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2. PMID: 22895183
  14. E-cadherin is necessary for localization of DLG1 but not phosphorylated MEK2 to the midbody ring during cytokinesis. PMID: 22185284
  15. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. PMID: 21969554
  16. hDlg acts as a MEK2-specific scaffold protein for the ERK signaling pathway. PMID: 21615688
  17. Data report the full-length structure of MEK2 obtained by homology modeling and molecular dynamics simulations. PMID: 21509657
  18. In the absence of other MKK, MEK2 is sufficient for SK-MEL-28 cell proliferation and anchorage-dependent growth. PMID: 21365009
  19. ETS1 is probably mediating high CIP2A expression in human cancers with increased EGFR-MEK1/2-ERK pathway activity PMID: 21445343
  20. familial inheritance of cardiofaciocutaneous syndrome with MEK2 mutation PMID: 21178588
  21. MEK1 and MEK2 play a part in the induction of the proinflammatory cytokine. PMID: 20837746
  22. This first reported case of a vertically transmitted functional Cardio-facio-cutaneous syndrome MEK mutation. PMID: 20358587
  23. MEK2 activity ad dual-phosphorylation were undetectable in expanding and self-renewing hematopoietic progenitors (HP). Adding IL-3, inducing maturation and cell death in HP, led to sustained high levels of MEK2 activity and dual-phosphorylation. PMID: 12032872
  24. MK2 phosphorylates TSC2, which creates a 14-3-3 binding site and thus regulates the cellular function of the TSC2 tumor suppressor protein PMID: 12582162
  25. MAPK activated protein kinase-2 mediates both ERK- and p38 MAPK-dependent neutrophil responses. PMID: 14499342
  26. HuR and MK2 in regulating the expression of uPA and uPAR genes at the posttranscriptional level PMID: 14517288
  27. Results suggest a physiological link between beta-dystroglycan and mitogen-activated protein kinase kinase 2 (MEK2), and localize MEK with dystroglycan in membrane ruffles. PMID: 15071496
  28. The ability of constitutively-active human MEK2 to stimulate ERK phosphorylation and to induce the neoplastic transformation of NIH 3T3 cells required the integrity of the D-site was found. PMID: 15979847
  29. These data suggest a role for mitochondrially generated reactive oxygen species and Ca(2+) in the redox cell signaling path-ways, leading to ERK activation and adaptation of the pathological stress mediated by oxidized lipids such as lysoPC. PMID: 16651638
  30. 3 novel mutations for MEK2 (L46_E55del, K61T, A62P) were identified in 15 patients with cardio-facio-cutaneous syndrome. PMID: 17704260
  31. Spectrum of MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations PMID: 19156172
  32. MEK2 interacts with ERK1. This interaction is mediated via a conserved N-terminal docking site in MEK2. PMID: 11134045

Show More

Hide All

Involvement in disease
Cardiofaciocutaneous syndrome 4 (CFC4)
Subcellular Location
Cytoplasm. Membrane; Peripheral membrane protein.
Protein Families
Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase subfamily
Database Links

HGNC: 6842

OMIM: 601263

KEGG: hsa:5605

STRING: 9606.ENSP00000262948

UniGene: Hs.465627

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To